Microbix Biosystems Inc. (TSE:MBX – Get Free Report) shares fell 3.8% during mid-day trading on Thursday following insider selling activity. The stock traded as low as C$0.49 and last traded at C$0.50. 188,134 shares traded hands during trading, a decline of 36% from the average session volume of 294,601 shares. The stock had previously closed at C$0.52.
Specifically, Director Cameron Lionel Groome sold 200,000 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of C$0.43, for a total value of C$86,500.00.
Microbix Biosystems Price Performance
The stock has a market capitalization of C$66.98 million, a PE ratio of 12.25 and a beta of 0.34. The company has a quick ratio of 5.57, a current ratio of 6.62 and a debt-to-equity ratio of 22.68. The stock’s 50-day moving average is C$0.38 and its 200 day moving average is C$0.35.
About Microbix Biosystems
Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.
Featured Stories
- Five stocks we like better than Microbix Biosystems
- Technology Stocks Explained: Here’s What to Know About Tech
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 3 Stocks to Consider Buying in October
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Microbix Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbix Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.